Shanghai-based biopharmaceutical company Genor Biopharma has completed a US$160 million Series B round financing led by existing investor Hillhouse Capital. New investors in the round include Temasek, CR-CP Life Science Fund, Haitong Kaiyuan Investment, and Cavenham PE. Proceeds of this financing will be used for the promotion of clinical projects in existing product pipelines, the […]

Hillhouse Capital Leads $160M Series B Round In Genor Biopharma comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.